| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:35 UTC |
|---|
| HMDB ID | HMDB0014343 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Oseltamivir |
|---|
| Description | Oseltamivir is only found in individuals that have used or taken this drug. It is an acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. [PubChem]Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. |
|---|
| Structure | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-Oseltamivir | ChEBI | | Agucort | ChEBI | | Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate | ChEBI | | GS-4104 | ChEBI | | HSDB 7433 | ChEBI | | Oseltamivirum | ChEBI | | Tamiflu | ChEBI | | Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid | Generator | | Oseltamivir phosphate | HMDB |
|
|---|
| Chemical Formula | C16H28N2O4 |
|---|
| Average Molecular Weight | 312.4045 |
|---|
| Monoisotopic Molecular Weight | 312.204907394 |
|---|
| IUPAC Name | ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate |
|---|
| Traditional Name | oseltamivir |
|---|
| CAS Registry Number | 204255-11-8 |
|---|
| SMILES | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |
|---|
| InChI Identifier | InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1 |
|---|
| InChI Key | VSZGPKBBMSAYNT-RRFJBIMHSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Gamma amino acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Gamma amino acid or derivatives
- Enoate ester
- Acetamide
- Alpha,beta-unsaturated carboxylic ester
- Carboxamide group
- Carboxylic acid ester
- Secondary carboxylic acid amide
- Dialkyl ether
- Ether
- Monocarboxylic acid or derivatives
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Primary aliphatic amine
- Organopnictogen compound
- Amine
- Organic oxygen compound
- Organic nitrogen compound
- Primary amine
- Organic oxide
- Hydrocarbon derivative
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.69 g/L | Not Available | | LogP | 1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.44 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.9261 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.98 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 47.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1938.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 201.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 147.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 157.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 89.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 428.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 404.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 109.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 977.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 423.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1325.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 276.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 292.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 255.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 171.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 24.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Oseltamivir,1TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N[Si](C)(C)C)C1 | 2381.0 | Semi standard non polar | 33892256 | | Oseltamivir,1TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N[Si](C)(C)C)C1 | 2282.1 | Standard non polar | 33892256 | | Oseltamivir,1TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N[Si](C)(C)C)C1 | 3352.8 | Standard polar | 33892256 | | Oseltamivir,1TMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N)C1 | 2307.4 | Semi standard non polar | 33892256 | | Oseltamivir,1TMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N)C1 | 2211.1 | Standard non polar | 33892256 | | Oseltamivir,1TMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N)C1 | 3295.4 | Standard polar | 33892256 | | Oseltamivir,2TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N[Si](C)(C)C)C1 | 2334.0 | Semi standard non polar | 33892256 | | Oseltamivir,2TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N[Si](C)(C)C)C1 | 2390.2 | Standard non polar | 33892256 | | Oseltamivir,2TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N[Si](C)(C)C)C1 | 2873.6 | Standard polar | 33892256 | | Oseltamivir,2TMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N([Si](C)(C)C)[Si](C)(C)C)C1 | 2449.0 | Semi standard non polar | 33892256 | | Oseltamivir,2TMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N([Si](C)(C)C)[Si](C)(C)C)C1 | 2401.7 | Standard non polar | 33892256 | | Oseltamivir,2TMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N([Si](C)(C)C)[Si](C)(C)C)C1 | 3166.8 | Standard polar | 33892256 | | Oseltamivir,3TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N([Si](C)(C)C)[Si](C)(C)C)C1 | 2404.4 | Semi standard non polar | 33892256 | | Oseltamivir,3TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N([Si](C)(C)C)[Si](C)(C)C)C1 | 2511.4 | Standard non polar | 33892256 | | Oseltamivir,3TMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C)[C@@H](N([Si](C)(C)C)[Si](C)(C)C)C1 | 2739.1 | Standard polar | 33892256 | | Oseltamivir,1TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N[Si](C)(C)C(C)(C)C)C1 | 2559.1 | Semi standard non polar | 33892256 | | Oseltamivir,1TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N[Si](C)(C)C(C)(C)C)C1 | 2464.0 | Standard non polar | 33892256 | | Oseltamivir,1TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N[Si](C)(C)C(C)(C)C)C1 | 3340.9 | Standard polar | 33892256 | | Oseltamivir,1TBDMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N)C1 | 2507.7 | Semi standard non polar | 33892256 | | Oseltamivir,1TBDMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N)C1 | 2396.9 | Standard non polar | 33892256 | | Oseltamivir,1TBDMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N)C1 | 3315.8 | Standard polar | 33892256 | | Oseltamivir,2TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N[Si](C)(C)C(C)(C)C)C1 | 2709.4 | Semi standard non polar | 33892256 | | Oseltamivir,2TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N[Si](C)(C)C(C)(C)C)C1 | 2745.4 | Standard non polar | 33892256 | | Oseltamivir,2TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N[Si](C)(C)C(C)(C)C)C1 | 3049.9 | Standard polar | 33892256 | | Oseltamivir,2TBDMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1 | 2854.9 | Semi standard non polar | 33892256 | | Oseltamivir,2TBDMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1 | 2755.5 | Standard non polar | 33892256 | | Oseltamivir,2TBDMS,isomer #2 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1 | 3217.3 | Standard polar | 33892256 | | Oseltamivir,3TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1 | 3043.8 | Semi standard non polar | 33892256 | | Oseltamivir,3TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1 | 3021.8 | Standard non polar | 33892256 | | Oseltamivir,3TBDMS,isomer #1 | CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](N(C(C)=O)[Si](C)(C)C(C)(C)C)[C@@H](N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C1 | 3011.0 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Oseltamivir GC-MS (Non-derivatized) - 70eV, Positive | splash10-05bo-9280000000-03554fbfb24a606e4a9a | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Oseltamivir GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-QTOF , positive-QTOF | splash10-01t9-0193000000-f5d60d35ef59bb0d3d88 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-QTOF , positive-QTOF | splash10-014i-0930000000-4bafe71e1cfce532c69e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-QTOF , positive-QTOF | splash10-014i-0900000000-b47b81a2da926f1b38a0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-QTOF , positive-QTOF | splash10-01bi-0900000000-e54a66b05b36ac125c76 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-QTOF , positive-QTOF | splash10-00dr-0900000000-a088a5ae7a49e423f645 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-004i-0090000000-a4689c9d2708c9864683 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-07fr-0393000000-c4ca6313b8a95857501f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-014i-0920000000-274bd00e87c126ea0431 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-014i-1900000000-ab2b530339386266bb5e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-00y3-3900000000-503de5f1484e1733b933 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-006x-6900000000-c732121f239f135b134c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-006x-9600000000-414288f436e77a96401f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-07fr-0393000000-782bc585f56c5193cc4e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-014i-0920000000-2a6c0c1f08190d6bbc0f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-014i-1900000000-3ea178c0a288c37e3e79 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-00y3-3900000000-0c790adae380f41f557a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-006x-6900000000-793d9a5e1ce9de381e4f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-006x-9600000000-ebf8dd7bcfb3a4844078 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oseltamivir LC-ESI-ITFT , positive-QTOF | splash10-004i-0090000000-f5e9b54d2909b3aff88d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oseltamivir 10V, Positive-QTOF | splash10-044j-1092000000-a5c51c03276e29381b54 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oseltamivir 20V, Positive-QTOF | splash10-0gi0-1290000000-855d80ff3dbaf863b55b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oseltamivir 40V, Positive-QTOF | splash10-00di-9720000000-3020e017c27cf5688ae5 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oseltamivir 10V, Negative-QTOF | splash10-03di-2089000000-aca6af58f0479c615bbc | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oseltamivir 20V, Negative-QTOF | splash10-02t9-2091000000-dafdec8458549b80e2b6 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oseltamivir 40V, Negative-QTOF | splash10-0ap1-9830000000-e6541c125795bb30888f | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004 Aug 28-Sep 3;364(9436):759-65. [PubMed:15337401 ]
- Chokephaibulkit K, Uiprasertkul M, Puthavathana P, Chearskul P, Auewarakul P, Dowell SF, Vanprapar N: A child with avian influenza A (H5N1) infection. Pediatr Infect Dis J. 2005 Feb;24(2):162-6. [PubMed:15702046 ]
- Ward P, Small I, Smith J, Suter P, Dutkowski R: Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005 Feb;55 Suppl 1:i5-i21. [PubMed:15709056 ]
- de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005 Dec 22;353(25):2667-72. [PubMed:16371632 ]
|
|---|